11 stories mentioning CORTUpdated 20d ago
Every FINWIRES story that references CORT, newest first.
William Guyer, Chief Development Officer, on June 02, 2026, sold 20,000 shares in Corcept Therapeutics (CORT) for $1,412,000. Following the Form 4 filing with the SEC, Guyer has control over a total of 3,985 common shares of the company, with 3,985 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1088856/000119312526257618/xslF345X05/ownership.xml
Joseph Douglas Lyon, Chief Accounting and Technology Officer, on May 27, 2026, sold 5,000 shares in Corcept Therapeutics (CORT) for $325,000. Following the Form 4 filing with the SEC, Lyon has control over a total of 6,230 common shares of the company, with 6,230 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1088856/000119312526248977/xslF345X05/ownership.xml
Sean Maduck, President of Corcept Endocrinology, on May 27, 2026, sold 75,000 shares in Corcept Therapeutics (CORT) for $4,918,944. Following the Form 4 filing with the SEC, Maduck has control over a total of 118,694 common shares of the company, with 8,977 shares held directly and 109,717 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1088856/000119312526248967/xslF345X05/ownership.xml
Healthcare stocks rose late Wednesday afternoon with the NYSE Healthcare Index gaining 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.3%.The iShares Biotechnology ETF (IBB) added 0.5%.In corporate news, BioNTech's (BNTX) cancer-drug pipeline is showing stronger early results and is approaching several important clinical milestones, improving confidence in the company's long-term outlook, UBS Securities said. BioNTech shares rose 1.4%.Corcept Therapeutics (CORT) shares jumped 9.7% after the company said it will resubmit its new drug application to the US Food and Drug Administration in the coming weeks for relacorilant to treat Cushing's syndrome.Boston Scientific (BSX) shares slumped 12% after CEO Mike Mahoney said this year has been "a bit more of a challenge" than anticipated.Guardant Health (GH) shares gained 5.6% after the company said its Shield blood test has been included in the American Cancer Society's updated Colorectal Cancer Screening guidelines.
Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index up 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.2%.The iShares Biotechnology ETF (IBB) added 0.5%.In corporate news, Corcept Therapeutics (CORT) shares jumped past 6% after the firm said Wednesday it will resubmit its new drug application to the US Food and Drug Administration in the coming weeks for relacorilant to treat Cushing's syndrome, also known as hypercortisolism.Boston Scientific (BSX) shares slumped 12% after Chief Executive Mike Mahoney said this year has been "a bit more of a challenge" than anticipated.Guardant Health (GH) shares gained 5.8% after the firm said its Shield blood test has been included in the American Cancer Society's updated Colorectal Cancer Screening guidelines.
Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index up 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.2%.The iShares Biotechnology ETF (IBB) added 0.4%.In corporate news, Corcept Therapeutics (CORT) shares jumped past 6% after the firm said Wednesday it will resubmit its new drug application to the US Food and Drug Administration in the coming weeks for relacorilant to treat Cushing's syndrome, also known as hypercortisolism.
Corcept Therapeutics (CORT) said Wednesday it will resubmit its new drug application to the US Food and Drug Administration in the coming weeks for relacorilant to treat Cushing's syndrome, also known as hypercortisolism.The company said it will resubmit the NDA based on positive outcomes of additional analyses of the application data, which were conducted following issuance of a complete response letter.The FDA notified the company to expect a Prescription Drug User Fee Act date six months following the application submission, according to a statement.Price: $64.86, Change: $+4.50, Percent Change: +7.46%
Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index adding 0.9% and the State Street Healthcare Select Sector SPDR ETF (XLV) increasing 0.7%.The iShares Biotechnology ETF (IBB) rose 0.3%.In corporate news, Corcept Therapeutics (CORT) shares rose past 11% after UBS Securities upgraded the stock to buy from neutral and raised its price target to $72 per share from $44.Ironwood Pharmaceuticals (IRWD) fell 10% after the company said Gregory Martini is resigning from his role as chief financial officer, effective May 15.Personalis (PSNL) shares jumped 6% after the firm said the Molecular Diagnostic Services Program of the Centers for Medicare & Medicaid Services has expanded coverage for its NeXT Personal minimal residual disease test.Assertio (ASRT) shares rose 3.4% after the company said Wednesday it has agreed to be acquired by Zydus Lifesciences subsidiary Zydus Worldwide DMCC in an all-cash tender offer valued at about $166.4 million.
Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index adding 0.9% and the State Street Healthcare Select Sector SPDR ETF (XLV) increasing 0.7%.The iShares Biotechnology ETF (IBB) rose 0.3%.In corporate news, Corcept Therapeutics (CORT) shares climbed past 12% after UBS Securities upgraded the stock to buy from neutral and raised its price target to $72 per share from $44.
Corcept Therapeutics (CORT) shares rose 11.6% in Wednesday trading after UBS Securities upgraded the stock to buy from neutral and adjusted its price target to $72 per share from $44.Trading volume stood at over 1.2 million shares compared with a daily average of about 1.7 million.Price: $57.11, Change: $+5.95, Percent Change: +11.62%
Corcept Therapeutics (CORT) has an average rating of overweight and mean price target of $79.25, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
